MX2016010411A - Compuestos agonistas de gpr142. - Google Patents
Compuestos agonistas de gpr142.Info
- Publication number
- MX2016010411A MX2016010411A MX2016010411A MX2016010411A MX2016010411A MX 2016010411 A MX2016010411 A MX 2016010411A MX 2016010411 A MX2016010411 A MX 2016010411A MX 2016010411 A MX2016010411 A MX 2016010411A MX 2016010411 A MX2016010411 A MX 2016010411A
- Authority
- MX
- Mexico
- Prior art keywords
- agonist compounds
- group
- gpr142 agonist
- gpr142
- ch2chf2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula (ver Fórmula) en donde R se selecciona a partir del grupo que consiste de CH3, CH(CH3)2, CH2CN, CH2CHF2, CH2CF3, (ver Fórmula) CH2CH2OCH3 y CH2C(O)OCH(CH3)2; R1 se selecciona a partir del grupo que consiste de CF3, OCF3 y CI; R2 se selecciona a partir del grupo que consiste de H y F; o una sal del mismo farmacéuticamente aceptable.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2014/072083 WO2015120610A1 (en) | 2014-02-14 | 2014-02-14 | Gpr142 agonist compound |
PCT/CN2015/071286 WO2015120768A1 (en) | 2014-02-14 | 2015-01-22 | Gpr142 agonist compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016010411A true MX2016010411A (es) | 2016-10-17 |
Family
ID=53799520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016010411A MX2016010411A (es) | 2014-02-14 | 2015-01-22 | Compuestos agonistas de gpr142. |
Country Status (10)
Country | Link |
---|---|
US (1) | US9861613B2 (es) |
EP (1) | EP3105207B1 (es) |
JP (1) | JP6298172B2 (es) |
CN (1) | CN106170478B (es) |
AU (1) | AU2015218135B2 (es) |
CA (1) | CA2935109A1 (es) |
EA (1) | EA201691265A1 (es) |
ES (1) | ES2693545T3 (es) |
MX (1) | MX2016010411A (es) |
WO (2) | WO2015120610A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016138631A1 (en) | 2015-03-03 | 2016-09-09 | Eli Lilly And Company | Imidazo benzamide compounds |
WO2018014337A1 (en) * | 2016-07-22 | 2018-01-25 | Eli Lilly And Company | 3-Chloro-N- [ (1R, 3S) -3- [5- (3, 5-dimethylimidazol-4-yl) -4H-1, 2, 4-triazol-3-yl] cyclohexyl] -N-methyl-benzamide |
WO2020007729A1 (en) | 2018-07-04 | 2020-01-09 | Boehringer Ingelheim International Gmbh | Triazole benzamide derivatives as gpr142 agonists |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2551909C (en) * | 2004-02-12 | 2011-10-11 | Transtech Pharma, Inc. | Substituted azole derivatives, compositions, and methods of use |
US20070032475A1 (en) * | 2005-04-15 | 2007-02-08 | Ye Xiaocong M | Novel compounds useful for bradykinin B1 receptor antagonism |
US7754717B2 (en) | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
US20090270394A1 (en) * | 2008-04-28 | 2009-10-29 | Galemmo Jr Robert | Cyclylamine derivatives as calcium channel blockers |
US8188098B2 (en) * | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
EP2404896A1 (en) * | 2009-03-05 | 2012-01-11 | Shionogi&Co., Ltd. | Cyclohexane derivative having npy y5 receptor antagonism |
AR079170A1 (es) * | 2009-12-10 | 2011-12-28 | Lilly Co Eli | Compuesto de ciclopropil-benzamida-imidazo-benzazepina inhibidor de diacil-glicerol aciltransferasa, sal del mismo, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de obesidad o para mejorar la sensibilidad a insulina y compuesto intermedio par |
-
2014
- 2014-02-14 WO PCT/CN2014/072083 patent/WO2015120610A1/en active Application Filing
-
2015
- 2015-01-22 ES ES15749214.1T patent/ES2693545T3/es active Active
- 2015-01-22 CA CA2935109A patent/CA2935109A1/en not_active Abandoned
- 2015-01-22 EA EA201691265A patent/EA201691265A1/ru unknown
- 2015-01-22 CN CN201580008473.9A patent/CN106170478B/zh not_active Expired - Fee Related
- 2015-01-22 US US15/116,230 patent/US9861613B2/en not_active Expired - Fee Related
- 2015-01-22 WO PCT/CN2015/071286 patent/WO2015120768A1/en active Application Filing
- 2015-01-22 EP EP15749214.1A patent/EP3105207B1/en active Active
- 2015-01-22 JP JP2016551720A patent/JP6298172B2/ja not_active Expired - Fee Related
- 2015-01-22 AU AU2015218135A patent/AU2015218135B2/en not_active Expired - Fee Related
- 2015-01-22 MX MX2016010411A patent/MX2016010411A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2015218135A1 (en) | 2016-07-14 |
EP3105207B1 (en) | 2018-08-22 |
WO2015120610A1 (en) | 2015-08-20 |
EP3105207A4 (en) | 2017-06-21 |
AU2015218135B2 (en) | 2017-06-08 |
EP3105207A1 (en) | 2016-12-21 |
ES2693545T3 (es) | 2018-12-12 |
US9861613B2 (en) | 2018-01-09 |
CA2935109A1 (en) | 2015-08-20 |
US20170165234A1 (en) | 2017-06-15 |
CN106170478A (zh) | 2016-11-30 |
WO2015120768A1 (en) | 2015-08-20 |
EA201691265A1 (ru) | 2016-11-30 |
JP2017505797A (ja) | 2017-02-23 |
JP6298172B2 (ja) | 2018-03-20 |
CN106170478B (zh) | 2019-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019501842A1 (en) | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors | |
JOP20180113A1 (ar) | مركبات ,تركيبات وطرق | |
PH12016501007A1 (en) | Substituted benzamides and methods of use thereof | |
SG10201809518QA (en) | Processes of preparing a jak1 inhibitor and new forms thereto | |
NZ729005A (en) | Aminopyrimidinyl compounds as jak inhibitors | |
MX2018001430A (es) | Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca). | |
MX2016011992A (es) | Derivados de piperidina-diona. | |
MX2016015862A (es) | Compuestos inhibidores de la cinasa de union a tank. | |
MX2018001890A (es) | Compuestos biciclicos como inhibidores de autotaxina (atx). | |
MY177574A (en) | New octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors | |
WO2014144545A3 (en) | Substituted benzoxazoles and methods of use thereof | |
MA40059A (fr) | Inhibiteurs de la phosphatidylinositol 3-kinase | |
TN2018000020A1 (en) | Colony stimulating factor-1 receptor (csf-1r) inhibitors. | |
PH12016501517B1 (en) | Tetrazolone-substituted dihydropyridinone mgat2 inhibitors | |
MA39956A (fr) | Analogues du benzomorphane et leur utilisation | |
MX2019010980A (es) | Antagonistas del receptor opioide kappa y productos y metodos relacionados al mismo. | |
MX369501B (es) | Proceso para la preparación de 5-fluoro-1h-pirazoles partiendo de hexafluoropropeno. | |
MX2016010973A (es) | Compuestos de aminocarbonilcarbamato. | |
MX2015017156A (es) | Inhibidores de bace. | |
MX2015015562A (es) | Dihidropiridinona como inhibidores de monoacilglicerol aciltransferasa 2. | |
MX2016008909A (es) | Compuestos de isopropil triazolo piridina. | |
MX2016015543A (es) | Proceso para la preparacion de 5-fluoro-1h-pirazoles a partir de hexafluoropropeno. | |
NZ739518A (en) | Compounds useful for inhibiting ror-gamma-t | |
EA201892235A1 (ru) | Гранулированная композиция для перорального применения | |
MX2016010411A (es) | Compuestos agonistas de gpr142. |